Biovail loses effort to stop generic Wellbutrin

Biovail has lost a last-ditch attempt to prevent copycat versions of its popular antidepressant Wellbutrin from hitting the market. A federal judge has ruled against a move to gain a temporary restraining order and an injunction against the FDA to prevent it from approving a generic. The ruling clears the path for Anchen to start selling a competing generic.

- here's the AP report on the ruling

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.